Pilot Phase II Study of Sandostatin LAR in Patients with Advanced Hepatocellular Carcinoma to assess toxicity and improve survival

Trial Profile

Pilot Phase II Study of Sandostatin LAR in Patients with Advanced Hepatocellular Carcinoma to assess toxicity and improve survival

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Octreotide (Primary)
  • Indications Liver cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 08 May 2009 Status changed from completed to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 06 Nov 2007 Status change
    • 06 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top